Federal Medical Cannabis Protections Approved in Congress
Key Takeaway
The US Senate voted to send President Trump legislation continuing federal protections for state-legal medical cannabis programs, extending the Rohrabacher-Blumenauer amendment that prevents the DOJ from using appropriated funds to prosecute compliant medical operators. The bill notably did not include a previously proposed rider that would have blocked Trump's cannabis rescheduling executive order. The continuation of medical program protections has been an annual must-pass item for the industry since 2014, though it offers no protection to adult-use operators. For cannabis businesses, the vote reinforces that federal enforcement risk for state-compliant medical operations remains low, but it does not extend to recreational programs or change Section 280E tax liability.
What This Means for Cannabis Businesses
Regulatory changes affect compliance requirements, licensing processes, and day-to-day operations for cannabis businesses. State-level rule changes can impact everything from product testing requirements to packaging standards to advertising restrictions. Operators should review their compliance procedures whenever new regulations take effect and work with consultants who specialize in their state's regulatory framework.
Find Help
Related News
Congressman Presses DOJ and DEA on Cannabis Rescheduling Timeline
Maryland Lawmakers Pass Bill Protecting Firefighters Who Use Medical Cannabis Off Duty
New Congressional Research Report on Cannabis Rescheduling Published
Congressional Research Service Releases Comprehensive Cannabis Rescheduling Report
This analysis is based on reporting by Marijuana Moment. Read the original article. CannaBizGuide provides original commentary and analysis - this is not legal or tax advice.